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ABSTRACT 
Hepatocellular carcinoma is the most common primary malignancy of the liver in adults. Hepatocellular carcinoma (HCC) represents one of the 
most challenging potentially curable tumors with high incidence, prevalence and mortality rates.  HCC is the fifth most common cancer and the 
third cause of cancer-related mortality worldwide. Its incidence is clearly arising comprised by the prevalence of major risk factors mainly 
hepatitis B and hepatitis C. The population at risk is composed of chronic liver patients at the stage of extensive fibrosis or cirrhosis. The 
monitoring programs of this population have allowed early detection of disease management to promote a radical therapy. Understanding the 
carcinogenic process and the mastery of the staging systems remain essential keys in diagnosis and treatment of HCC. Recent advances in 
diagnosis and new treatments have made important impacts on the disease by increasing survival rates and improving quality of life for HCC 
patients.  
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The liver is a vital organ of vertebrates and some other 
animals 1. In the human it is located in the upper right 
quadrant of the abdomen, below the diaphragm. The liver 
has a wide range of functions, including detoxification 
various metabolites, protein synthesis, and the production of 
biochemicals necessary for digestion. The liver's main job is 
to filter the blood from the digestive tract, before passing it 
to the rest of the body. The liver also detoxifies chemicals 
and metabolizes drugs. As it does so, the liver secretes bile 
that ends up back in the intestines. The liver also makes 
proteins important for blood clotting and other functions 2. 
Liver cancer is a tumour that initially forms in the tissue of 
the liver. Different types of liver cancer exist according to the 
type of cancerous cells. Hepatocellular carcinoma (HCC) is 
the most frequent type of liver cancer. It accounts for 90% of 
all liver cancers. Hepatocellular Carcinoma (HCC) is the sixth 
most common cancer worldwide, accounting for 7% of all 
cancers and an estimated incidence of 749,000 new cases 
every year. It is considered to be the third cause of cancer re-
lated deaths (692,000 cases). The highest incidence rates of 
HCC (around 85% of cases) are present in East Asia, sub-
Saharan Africa, and Melanesia 3. 
Hepatocellular carcinoma begins in hepatocytes, the main 
cells of the liver. Hepatocellular carcinoma is a malignant 
tumor composed of cells resembling hepatocytes; however, 
the resemblance varies with the degree of differentiation. 
Hepatocellular carcinoma is commonly associated with 
cirrhosis (Figure no-2). 
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Figure-1: Anatomy of the liver and surrounding organs 
 
 
Figure 2:   A- Cirrhotic liver with focal tumor; B- histological 
appearance. 
HEPATOCELLULAR CARCINOMA (LIVER CANCER): 
ANATOMY 
The liver is the largest organ in the abdominal cavity and the 
most complex. It consists of a myriad of individual 
microscopic functional units call lobules. The liver performs 
a variety of functions including the removal of endogenous 
and exogenous materials from the blood, complex metabolic 
processes including bile production, carbohydrate 
homeostasis , lipid metabolism, urea formation, and immune 
functions. The liver arises from the ventral mesogastrium 
and only the upper posterior surface is outside of that 
structure. The ligamentum teres and falciform ligament 
connect the liver to the anterior body wall. [3,4] The lesser 
omentum connects it to the stomach and the coronary and 
triangular ligaments to the diaphragm. The liver is smooth 
and featureless on the diaphragmatic surface and presents 
with a series of indentations on the visceral surface where it 
meets the right kidney, adrenal gland, inferior vena cava, 
hepatoduodenal ligament and stomach. The liver can be 
considered in terms of blood supply hepatocytes, Kupffer 
cells and biliary passages. The liver receives its blood supply 
from the portal vein andhepatic artery, the former providing 
about 75% of the total 1500 ml/min flow. Small branches 
from each vessel the terminal portal venule and the terminal 
hepatic arteriol enter each acinus at the portal triad. Pooled 
blood then flows through sinusoids between plates and 
hepatocytes in order to exchange nutrients 4.  
The hepatic vein carries efferent blood into the inferior vena 
cava and a supply of lymphatic vessels drains the liver. 
Parenchymal cells or hepatocytes comprise the bulk of the 
organ and carry out complex metabolic processes. 
Hepatocytes are responsible for the liver’s central role in 
metabolism (Figure no 3). These cells are responsible for the 
formation and excretion of bile; regulation of carbohydrate 
homeostasis; lipid synthesis and secretion of plasma 
lipoproteins; control of cholesterol metabolism; and 
formation of urea, serum albumin, clotting factors, enzymes, 
and numerous proteins. The liver also aids in the metabolism 
and detoxification of drugs and other foreign substances 4
 
 
Figure 3: A-Normal gross anatomy of a liver; B, histological slide; B’-histological view. 
Kupffer cells line the hepatic sinusoids and are part of the 
reticuloendothelial system, filtering out minute foreign 
particles, bacteria, and gut-derived toxins. They also play a 
role in immune processes that involve the liver. Biliary 
passages begin as tiny bile canaliculi formed by hepatocytes. 
These microvilli -lined structures progress into ductules, 
interlobular bile ducts, and larger hepatic ducts. Outside the 
porta hepatis, the main hepatic duct joins the cystic duct 
from the gallbladder to form the common bile duct, which 
drains into the duodenum. HCC cases are associated to 
cirrhosis secondary to chronic infection with either hepatitis 
B or C viruses4. 
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PATHOLOGY OF LUNG CANCER  
HCC may present as a unifocal, multifocal, or diffusely 
infiltrative tumor 5. All patterns demonstrate broad potential 
for vascular invasion. When associated with cirrhosis, HCC 
usually arises from malignant transformation of a 
regenerative nodule. 
 
Figure 4: Development of liver tumors and their evolution to 
HCC 
 There is stimulation to angiogenesis, and the tumor receives 
abundant arterial vascularization. The mean tumor 
duplication time is about 200 days 6. This time decreases as 
tumor increases. With up to 3 cm in size, HCC is generally 
well differentiated, encapsulated, and has low potential for 
blood vessel invasion. When it reaches approximately 5 cm 
in size, the nodule begins to loose differentiation and to 
exhibit microscopic vascular invasion, acquiring capacity to 
generate metastases 7,8 
SIGN AND SYMPTOMS OF LIVER CANCER 
Signs and symptoms of liver cancer often do not show up 
until the later stages of the disease, but sometimes they may 
show up sooner. If you go to your doctor when you first 
notice symptoms, your cancer might be diagnosed earlier, 
when treatment is most likely to be helpful. Some of the most 
common symptoms of liver cancer are: 
 ● Weight loss (without trying)  
● Loss of appetite  
● Feeling very full after a small meal  
● Nausea or vomiting  
● An enlarged liver, felt as a mass under the ribs on the right 
side  
● An enlarged spleen, felt as a mass under the ribs on the left 
side  
● Pain in the abdomen or near the right shoulder blade  
● Swelling or fluid build-up in the abdomen  
● Itching  
● Yellowing of the skin and eyes (jaundice) Some other 
symptoms can include fever, enlarged veins on the belly that 
can be seen through the skin, and abnormal bruising or 
bleeding 7,8.  
HEPATOCELLULAR CARCINOMA (LIVER CANCER): 
CAUSES 9,10,11 
Hepatitis B and C 
The two most important etiological factors contributing to 
hepatocelluar carcinoma are hepatitis B and hepatitis C 
(Figure 5). In parts of China and Taiwan, 80% of 
hepatocellular carcinoma is due to hepatitis B. In the United 
States and Europe, hepatitis C and hepatitis B contribute 
equally to disease cases. In Japan, where the prevalence of 
hepatitis B and hepatitis C is similar, the incidence of 
hepatocellular carcinoma is higher in patients with hepatitis 
C compared to hepatitis B (10.4% vs. 3.9%). The 
pathogenesis of hepatocellular carcinoma in the presence of 
hepatitis B virus may be due to increased cell turnover from 
chronic liver disease, or a combination of processes specific 
to the hepatitis B virus. These may include integration of the 
hepatitis B DNA genome into the host genome, thereby 
disrupting the regulatory elements of cell cycling, or via 
transactivation of host oncogenes by either HBx protein or a 
truncated protein derived from pre-S2/S region of hepatitis 
B genome. The pathogenesis of hepatocellular carcinoma in 
hepatitis C is less understood. It is possible that some of 
these patients had previous exposure to hepatitis B virus. 
 
Figure 5: Causes of hepatocellular carcinoma 
Cirrhosis 
Cirrhosis, irrespective of its etiology , is a risk factor for the 
development of hepatocellular carcinoma. The risk is 3–4 
times higher in patients with cirrhosis compared to those 
with chronic hepatitis in a given population. An increase in 
hepatocellular proliferation may lead to the activation of 
oncogenes and mutation of tumor suppressor genes. These 
changes, in turn, may initiate hepatocarcinogeneses . 
Other Factors 
Other etiological factors affecting disease incidence include 
aflatoxins, alcohol, hemochromatosis , and anabolic steroid 
use. 
HEPATOCELLULAR CARCINOMA (LIVER CANCER): 
DIAGNOSIS 
Clinical Features 
The classic clinical features of HCC include right upper 
quadrant pain and weight loss. Other clinical scenarios that 
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suggest this diagnosis include worsening liver function in a 
patient known to have cirrhosis, acute abdominal 
catastrophe from rupture of a liver tumor with intra-
abdominal bleeding, and some rare extrahepatic 
manifestations 12. 
Alpha-Fetoprotein (AFP) 
Alpha-fetoprotein levels may be assessed by a blood test. 
Alpha-fetoprotein (AFP) is a tumor marker that is elevated in 
60–70% of patients with hepatocellular carcinoma. 
Normally, levels of AFP are below 10 ng/ml, but marginal 
elevations (10–100) are common in patients with chronic 
hepatitis. However, all patients with elevated AFP should be 
screened (abdominal ultrasound, CT scan or MRI) for 
hepatocellular carcinoma, especially if there has been an 
increase from baseline levels. In our experience, a steadily 
rising AFP is almost diagnostic of hepatocellular carcinoma. 
The specificity of AFP is very high when the levels are above 
400 ng/ml. Undifferentiated teratocarcinoma and embryonal 
cell carcinoma of the testis or ovary may give false-positive 
results and should be considered in the differential diagnosis 
of elevated AFP 13. 
Radiographic Diagnosis 
The diagnostic accuracy of ultrasound, CT, magnetic 
resonance imaging (MRI) and angiography is dependent on a 
number of variables: expertise of the operator (especially 
with ultrasound), sophistication of equipment and technique, 
presence of cirrhosis and, most importantly, experience of 
the interpreter 14,15. 
HEPATOCELLULAR CARCINOMA (LIVER CANCER): 
THERAPY 
HCC recently appeared as a potentially curable disease with 
many treatment options that depend on patient factors as 
the performance status and operability, and tumor related 
factors like size, location and the presence or absence of 
extratumoral spread. 
 Herbal Remedy For Liver Cancer Herbal drugs have 
become increasingly popular and their use is wide-
spread. Herbal medicines have been used in the 
treatment of liver diseases for a long time so the 
maintenance of a healthy liver is essential for the overall 
well being of an individual. 16 Liver injury induced by 
toxins is more common nowadays. Herbal remedies are 
focused in the pharmaceutical industry to evolve a safe 
route for liver disorders. Therefore, hepatoprotective 
natural products are Andrographic paniculata, 
Chamomile capitula , Silybum marianum, Coccinia 
grandis, Flacourtia indica, Wedelia calendulacea, Annona 
squamosa, Prostechea michuacana, Ficus carica, 
Lepidium sativum, Sargassum polycystum, Solanum 
nigrum, swertia chirata, Phyllanthus emblica, Curcuma 
longa, Picrorhiza kurroa 17. 
 Liver Resection. Orthotopic liver transplantation (OLT) 
is the curative options in which both the tumor and the 
underlying liver disease are removed. Therefore, it is 
the treatment of choice for patients with hepatic 
cirrhosisrelated hepatocellular carcinoma.18. 
Unfortunately, not all patients are eligible for liver resection. 
Resection is not indicated when: 1) the tumor has spread to 
other parts of the liver or the body, 2) the size or location of 
the tumor (near major blood vessels) precludes it from being 
safely removed without compromising function of the 
remainder of the liver, 3) the associated cirrhosis or disease 
limits the ability to safely operate upon or remove part of the 
liver, and 4) other medical conditions make surgery unsafe 
19. Excessive blood loss during liver resection not only 
increases the need for blood transfusion, with its associated 
problems, but increases the risk of structural injury and 
suboptimal tumor margin clearance by obscuring the 
surgical field. Newer surgical techniques of vascular 
isolation, as well as the use of intraoperative 
ultrasonography, have significantly reduced the need for 
blood transfusions and blood products in modern liver 
surgery. 
 
Figure 6: A-Hepatocellular carcinoma in healthy liver; B-
corresponding computed tomography (CT) scan. 
 
 Radiofrequency Ablation Percutaneous ablation with 
percutaneous ethanol injection (PEI) or radiofrequency 
ablation (RF) achieves complete responses in more than 
80% of tumours smaller than 3 cm in diameter and 
provide 5-year survival rates of 40–70%. new technique 
that makes use of a “heating” probe to destroy tumors 
within the liver. 
 
Figure 7: Radiofrequency ablation (RFA) in hepatocellular 
carcinoma. 
A thin probe is placed within the tumor, typically under 
ultrasound guidance. After deploying the tip array, an 
electrical current is applied, generating heat (80–100°C) that 
destroys the tumorThe best outcomes have been reported in 
Child–Pugh A patients with small single tumours, commonly 
less than 2 cm in diameter 20,21. 
 Palliative Therapy. Due to the implementation of 
prevention programs for HCC, patients are usually 
diagnosed in early stage. Nevertheless, some are 
detectable at an intermediate or advanced stage with 
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preserved liver function or not, multinodular disease 
exceeding the Milan criteria, with or without symptoms 
or extrahepatic spread manifested by absence of 
portal/node invasion or distant metastasis. For these 
patients, palliative therapies are proposed to reduce 
symptoms related to disease progression and improve 
survival. The general principle of palliative treatment is 
to prevent the blood supply to the HCC by blockage of 
the arterial system of liver22. These treatments include 
transarterial embolization (TAE), transarterial 
chemoembolization (TACE), intra-artery chemotherapy 
(IACT), and radiotherapy (external and internal). They 
can be usedas bridge to liver transplantation 23. 
 Cryosurgery Although surgical resection may afford the 
only potential for cure for patients with liver tumors, 
many patients may not be surgical candidates for a 
variety of reasons. Novel methods for local ablation 
have been developed with the goal of increasing the 
number of patients eligible for surgical therapy. Hepatic 
cryosurgery is one such interstitial therapy that has 
gained popularity in recent years. This technique relies 
on the in situ destruction of a defined area within the 
liver using liquid nitrogen at subzero temperatures. 
Although cryosurgery has been used in the past for the 
treatment of a variety of surface malignancies, recent 
advances in the ability to deliver liquid nitrogen deep 
within tissue using a closed-circuit insulated probe 
system, as well as improvements in intraoperative 
imaging using intraoperative ultrasound, have provided 
the capability for safe hepatic cryoablation 24. 
 
Figure 8: Cryosurgery of hepatocellular hematoma; B, 
corresponding ultrasoundshowing the probe in the tumor. 
Cryosurgery is a technique utilizing subzero temperatures to 
destroy tumors. In most cases, the tumor is destroyed but 
not removed. The technique involves the placement of one or 
more probes (cryoprobe) into the tumor using ultrasound to 
guide the placement. Liquid nitrogen, at -190°C, is circulated 
in a closed system through the end of the probe creating an 
ice ball at the tip. The ice ball is allowed to encompass the 
tumor and approximately one-half-inch margin around it the 
tumor is frozen and thawed twice, potentially taking up to 30 
minutes. Following completion of the procedure, patients are 
monitored in the Intensive Care Unit overnight and remain 
in the hospital for 3–5 days. Cryosurgery is an operative 
procedure requiring general anesthesia. It may be performed 
alone or in conjunction with a liver resection25, 30. 
 Systemic Therapies. Parallel to the development of 
research concerning pathological and histological 
pathways leading to HCC, many drugs and hormonal 
therapy have been tested as agents inhibiting important 
signaling pathways in tumor cells and also angiogenesis 
in systemic therapy for HCC. Patients in intermediate or 
advanced stage who do not undergo curative surgical 
treatment and ablative techniques are candidates for 
these therapies. Systemic therapies have not 
unfortunately provided benefit effect or increased 
survival for patients with advanced HCC. Several clinical 
trials have been conducted on these agents searching an 
optimal therapy against advanced HCC, but there is no 
currently defined as a standard formula effective against 
advanced HCC. They can be used as single or combined 
hormonal or chemotherapy. The most used is the 
multikinase inhibitor sorafenib that was approved by 
the European Medicines Agency (EMEA) and the US 
Food and Drug Administration(FDA). These promising 
benefits in patients with metastaticdisease need further 
evaluation. Other therapeutic agentssuch as 
doxorubicin, epirubicin, mitoxantrone, cisplatin, 
gemcitabine, capecitabine, 5-Flu, Tamoxifen, and 
placebo.have been also used as single agent against 
advanced HCC.Some combined agents against HCC have 
been investigated,and the most known are cisplatin, 
doxorubicin, 5-Flu, and interferon-α (PIAF), gemcitabine 
and oxaliplatin (GEMOX), oxaliplatin and 5-
Flu/leucovorin (FOLFOX), capecitabine and oxaliplatin 
(XELOX). The results vary depending on the research 
groups, countries, and characteristics of the patients 
tested 26. 
 Liver Transplantation In patients with small tumors 
and advanced cirrhosis (Child B or Child C) the 
treatment of choice is liver transplantation. The 5-year 
survival in patients with small tumors (a single tumor 
less than 5 cm, or two tumors less than 3 cm) is 50–
60%. Poorly differentiated tumors that show vascular 
invasion, and large tumors have a poor prognosis.
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Figure 9: Liver transplantation; A, before, diseased liver; B, after, donor liver in place. 
 
Although the presence of tumors of both lobes was at one 
time considered a poor prognosis after livertransplantation, 
a recent study demonstrated that patients with bilobar 
disease have the same survival rates as patients with 
unilobar disease 27 
 Interventional Radiological Therapy Hepatic artery 
chemoradiation is by far the most commonly performed 
procedure in the treatment of unresectable liver tumors 
(i.e., those that are inoperable). Most hepatic tumors are 
supplied by the hepatic arterial system, as opposed to 
normal liver tissue, in which most of the blood supply 
comes from the portal venous system. 
Chemoembolization has several theoretical advantages 
over intravenous pump infusion therapy because it 
delivers highly concentrated drugs to the tumor itself 
and arrests blood flow, the latter prolonging contact 




Figure 10: A, B, Hepatic artery chemoembolization; A’, with corresponding angiogram. 
 
This technique deprives the tumor of its oxygen supply while 
achieving a drug concentration in the tumor 10–25 times 
greater than that which can be achieved by infusion alone. In 
addition, the “dwell time” for the drug is markedly 
prolonged, with measurable drug levels present as long as a 
month after chemoembolization 28, 30. 
 Percutaneous Ethanol Injection Ultrasound-guided 
percutaneous ethanol injection in hepatic tumors was 
first described in 1983. 
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Figure 11: Percutaneous ethanol injection 
Percutaneous ethanol injection has been used primarily to 
treat tumors less than 5 cm in diameter and patients with 
less than three lesions. It has been demonstrated that 
ethanol injection is more effective against hepatoma lesions 
than against metastatic lesions. The procedure is performed 
under ultrasound guidance. A small needle is inserted into 
the posterior aspect of the tumor, and ethanol is slowly 
injected into the lesion.Patients may receive one or two 
sessions per week until the tumor is completely saturated. 
Post-procedural imaging, including CT and MRI, is typically 
conducted after 1 month 29,30. 
 Cisplatin Gel Infusion Percutaneous cispatin gel 
infusion is a new and promising therapeutic option for 
the treatment of unresectable liver tumors. This 
technique was recently developed and is currently 
undergoing clinical trials in the United States. It is 
similar to percutaneous ethanol injection in that it is 
performed under ultrasound guidance. 
 
Figure 12: Percutaneous cisplatin gel infusion. 
A small needle is inserted directly into the deepest aspect of 
the tumor and the cisplatin gel is infused. The gel slowly 
diffuses throughout the tumor and acts as a carrier of the 
chemotherapeutic drug. Because this treatment method is 
undergoing initial clinical trials, strict enrollment criteria 
have been defined. Tumors greater than 7 cm cannot be 
treated using this technique 30. 
CONCLUSION 
The HCC remains a malignant disease leading to 
death.Significant progress has been made in the 
management of the disease. Because of its complexity, a 
multidisciplinary approach must be implemented to support 
the different aspects in HCC. A better control of epidemiology 
should better sit prevention programs in at-risk populations. 
A better understanding of the molecular and histological 
responsible for the occurrence of the disease should allow 
the development of new diagnostics and treatments more 
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